Silence Therapeutics PLC(SLN) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights • Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV Divesiran for Polycythemia Vera (PV) Zerlasiran for Cardiovascular Disease • Completed core Phase 3 readiness activities, including manufacturing and supply scale up. We continue to be in dialogues with potential third-party partners for Phase 3 development of zerlasiran as ...